HALO — Halozyme Therapeutics Inc
NASDAQ · Biotechnology · Biotechnology
- Latest Close
- $68.4
- 30-Day Move
- +10.5%
- Market Cap
- $7.6B
- Shares Outstanding
- 118,020,000
- P/E Ratio
- 24.02
- P/B Ratio
- 162.13
Halozyme Therapeutics Inc
A read-only Alphactor snapshot for Halozyme Therapeutics Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of 2026-04-22
Topline snapshot
Latest Close
$68.4
30-Day Move
+10.5%
Market Cap
$7.6B
Shares Outstanding
118,020,000
P/E Ratio
24.02
P/B Ratio
162.13
$68.40
+10.5%last 90 delayed daily bars
90D High
$82.22
90D Low
$61.23
Avg Volume
1,826,261
Gross margin is running at 83.6%, which gives a quick read on operating quality before you open the full model.
Net margin is 22.7%, useful for comparing HALO against peers in Biotechnology.
HALO is up 10.5% over the last 30 trading days shown on this page.
Latest operating income is $241M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$54.45
Rule of 40
63.1%
Latest Close
$68.4
30-Day Move
+10.5%
Market Cap
$7.6B
Shares Outstanding
118,020,000
P/E Ratio
24.02
P/B Ratio
162.13
ROE
649.2%
ROA
12.6%
Gross Margin
83.6%
Operating Margin
33.2%
Net Margin
22.7%
Debt / Equity
43.89
Current Ratio
4.66
Latest Revenue
$452M
Revenue
$452M
Gross Profit
$373M
Operating Income
$241M
Net Income
$-142M
Gross Margin
8362.0%
Net Margin
2269.0%
Current Ratio
4.66
Debt / Equity
43.89
Fair Value
$54.45
Upside / Downside
-20.4%
Signal
Overvalued
Implied Growth
12.1%
DCF
$92.65
EPV
$28.55
EV/Rev
$42.15
Growth Assumption
28.4%
Discount Rate
9.9%
Terminal Growth
2.0%
Base FCF
$357M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Moderate growth priced in
Altman Z
3.78
Safe
Piotroski
5
Moderate (4-6)
Cash Conversion
2.06x
Rule of 40
63.1%
Elite
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $660M | $268M | $202M | $235M |
| 2023-12-31 | $829M | $338M | $282M | $373M |
| 2024-12-31 | $1.0B | $551M | $444M | $468M |
| 2025-12-31 | $1.4B | $803M | $317M | $357M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Qube Research & Technologies
Filed 2025-05-15
--
--
BlackRock
Filed 2024-08-13
$923M
--
Vanguard Group
Filed 2025-11-07
$853M
-5.0%
Invesco
Filed 2026-02-19
$246M
+12.4%
Geode Capital Management
Filed 2025-11-12
$178M
-0.1%
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.